Table 2.
Baseline participant characteristics
| Fish oil (n = 6) median (IQR) | Placebo (n = 6) median (IQR) | |
|---|---|---|
| Age (years) | 68.50 (2.50) | 70.5 (6.11) |
| Sex (n) | ||
| Male | 3 | 4 |
| Female | 3 | 2 |
| Height (cm) | 166.80 (12.74) | 167.20 (8.22) |
| Mass (kg) | 85.00 (24.98) | 82.20 (24.05) |
| BMI (kg/m2) | 30.02 (6.07) | 31.84 (6.07) |
| Smoking status (n) | ||
| Never | 0 | 1 |
| Ex-smoker | 6 | 5 |
| mMRC score | 1.50 (1.00) | 1.00 (1.50) |
| Dyspnoea-12 (at rest) | 12 (16) | 8 (1.5) |
| Borg (dyspnoea, at rest) | 0.5 (0.25) | 0.25 (0.5) |
| FEV1/FVC | 0.59 (0.05) | 0.46 (0.02) |
| FEV1% predicted | 72.00 (13.00) | 50.00 (18.00) |
| Number of medications, total | 6 (2) | 5 (5) |
| Number COPD medications | 2 (1) | 3 (1) |
| Self-reported comorbidities | 4 (2) | 3 (2) |
| Charlson comorbidity scorea | 3 (1) | 4 (2) |
| RX-Risk-V | 11 (5) | 14 (12) |
aAge adjusted
BMI body mass index, COPD chronic obstructive pulmonary disease, FEV 1 /FVC forced expiratory volume in 1 s/forced vital capacity, FEV 1 % predicted forced expiratory volume in 1 s percent predicted, IQR interquartile range, mMRC modified Medical Research Council, RX-Risk-V validated prescription medication-based comorbidity index